


# Logic-gated Tmod™ CAR T trials for solid tumors

## How Tmod CAR T works

CAR T-cell therapies against solid tumors can be limited by a lack of tumor-specific antigens that discriminate normal cells from tumor cells, resulting in on-target, off-tumor toxicities.



Tmod cells may improve tumor selectivity and decrease toxicity by integrating 2 CARs: an activator that recognizes an antigen on both normal and tumor cells and a blocker that recognizes an antigen on normal cells that is often lost in tumor cells (HLA-A\*02). Thus, Tmod cells are logic-gated, protecting normal cells while allowing tumor cell killing.

Examples of activators include mesothelin (MSLN) and epidermal growth factor receptor (EGFR).

## We have three studies actively recruiting:



### BASECAMP-1 Pre-screening for Tmod CAR T studies

NCT04981119

- Pre-screening study for patients at high risk of relapse for incurable disease
- Patients can screen at any point in their treatment journey
- Human leukocyte antigen (HLA) loss of heterozygosity (LOH) screening
- Biomarker testing (as needed to confirm antigen expression)
- Apheresis, as appropriate, for eligible auto- or allogeneic Tmod CAR T programs

**Enrollment will not disrupt current therapy or change where the patient receives care.**

- Participants can complete apheresis early in their treatment journey and have autologous Tmod CAR T-cell investigational product prepared when they are ready for EVEREST-2

**BASECAMP-1 participants may screen for an interventional study after receiving at least one line of therapy and have measurable disease per RECIST v1.1.**

Interventional studies drawing from **BASECAMP-1**

### EVEREST-2

NCT06051695

Autologous Tmod CAR T

Open-label interventional Phase 1/2 Study in solid tumors that express MSLN and that have lost HLA-A\*02 expression

Evaluating multiple MSLN-targeting autologous Tmod CAR T products

### DENALI-1

NCT06682793


Allogeneic Tmod CAR T

Open-label interventional Phase 1/2 Study in solid tumors that express EGFR and have lost HLA-A\*02 expression

Evaluating A2B395, an EGFR-targeting allogeneic Tmod CAR T product

- Lymphodepletion is required up to 1 week prior to study treatment
- 7-day inpatient hospitalization required following investigational treatment
- Study participants will stay near the study center for up to 4-6 weeks after treatment for close safety monitoring
- Study assessments, including CT scans, biospecimen collection, and safety and disease response evaluation, will be done for up to 2 years after treatment

## Patient journey in BASECAMP-1



## Patient population in BASECAMP-1

- Age  $\geq 18$  years old with solid tumor cancer considered high risk for incurable relapse within the next 2 years
- No prior allogeneic stem cell transplant
- No prior solid organ transplant
- Suitable for cell therapy treatment (ECOG performance status 0 or 1, life expectancy  $\geq 3$  months, and adequate bone marrow reserve and hematologic, renal, and hepatic function not expected to worsen significantly within  $\leq 3$  months)

\*\*MSLN expression confirmed on BASECAMP-1

EVEREST-2	Pancreatic cancer	DENALI-1
	Ovarian cancer	
	Mesothelioma	
	Other tumor types known to express MSLN**	
	Non-small cell lung cancer	
Colorectal cancer	DENALI-1	
Triple-negative breast cancer		
Head and neck squamous cell cancer		
Renal cell cancer		
Other tumor types known to express EGFR		

## Contact

For more information about the A2 Bio clinical studies, including an animated video for patients, visit: [A2BioClinicalTrials.com](https://www.a2bio.com/clinical-trials)

To locate a nearby BASECAMP-1 study center, please visit: [clinicaltrials.gov/study/NCT04981119#contacts-and-locations](https://clinicaltrials.gov/study/NCT04981119#contacts-and-locations)

Recent results from these trials can be found here: [a2bio.com/science/posters/](https://www.a2bio.com/science/posters/)

To enroll a patient or for other questions, please contact: [ClinicalTrials@a2bio.com](mailto:ClinicalTrials@a2bio.com) or leave a voicemail at (310) 431-9180